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Baffling Butadiene
The United States was a nation at war in
1942, the demands ofwhich included quickly
establishing a number of industries aimed at
supplying crucial material for ensuring mili-
tarysuccess overseas. Critical among thesewas
the establishment of the synthetic rubber
industry, which began in 1942 under federal
sponsorship.
Just as it was in 1942, 1,3-butadiene, the
gaseous hydrocarbon commonly referred to
simply as butadiene, is an important major
commodity product of the petrochemical
industry. Butadiene has a pungent odor like
gasoline that can be detected at about one to
two parts per million (ppm). It is highly flam-
mable and is handled as a liquified com-
pressed gas. Its principal use is in the manu-
facture of butadiene-styrene copolymer elas-
tomer, ofwhich more than 60% is used for
tires. The elastomer is also used to prepare a
variety ofother synthetic rubber products and
chemicals such as adiponitrile, a nylon precur-
sor, and is used in the manufacture ofplastic
food wrappings, sponges, hoses and piping,
footwear, luggage, packaging, and a variety of
molded products.
In the United States, almost 100% ofthe
nearly 3 billion pounds of butadiene is pro-
duced as a co-product of ethylene manufac-
ture. Most butadiene is extracted from a
mixed butenes stream, or crude butadiene,
which is a by-product ofethylene production.
U.S. extraction facilities are located in Texas
and Louisiana. These extraction facilities are
typical petrochemical plants: treelike fraction-
ating towers predominate a steely maze of
pipelines and struc-
tures housing a vari-
ety ofpumps, reboil-
ers, heat exchangers,
valves, and bunker-
like control build-
ings. These struc-
tures are open air,
some covering up to
30 acres, but all hy-
drocarbons are fully
contained to prevent
fire andexplosion.
Occupational
exposures to butadi-
ene can occur during
production, storage,
and transport of the
monomeroritschem-
ical mixtures. Decon-
tamination and main-
tenance ofprocessing
equipment, sampling
and analyzing quality
control samples, and
loading or unloading Setting the wheels rolli
tank trucks or rail cars of Indiana, left, and '
are typical operations Jeffers unveilthefirst al
ing.
'Ru
II-sy
during which exposure may occur.
Equipment leaks account for 99.5% of the
atmospheric emissions of butadiene from
industry. Togetherwith the much larger mag-
nitude of butadiene emissions from vehicle
exhaust, industrial emissions may account for
localized "hot spots" within overall patterns of
human exposure. At the perimeter of the
industrial complex in Port Neches, Texas,
where butadiene and styrene-butadiene rub-
ber has been produced since the early 1940s,
levels as high as 2 ppm were detected in the
airas recentlyas 1990.
An estimated 3100workers are exposed to
butadiene in 11 U.S. production facilities,
which include crude, monomer, and terminal
facilities. Monomer plants are highly auto-
mated and involve fewer workers than the
otherfacilities. In addition to these are an esti-
mated 4200 workers at 34 butadiene-con-
sumingplants nationwide who are also poten-
tially directly exposed to the monomer. Data
compiled from a 1990 National Occupational
Exposure Survey by the National Institute of
Occupational Safety and Health suggest that
approximately 50,000 workers in end-user
industries arepotentiallyexposed to butadiene
through contact with a variety of butadiene
subproducts.
Controversy surrounding health effects of
occupational inhalation exposure to butadiene
is focused largely on its potential as a human
carcinogen. At the time of industry start-up
during World War II, human carcinogenicity
associated with butadiene exposure was
unknown. SinceJanuary 1976, when two for-
Cmer workers at adja-
Ecent synthetic rubber
o production facilities ~in Texas died of
leukemia, dozens of
scientific reports and
commentaries re-
garding butadiene
carcinogenicity have
appeared in the liter-
ature, the authors at
times crossing verbal
broadswords with an
almostaudible lank.
Caught in the
middle of this con-
troversy is the U.S.
Occupational Safety
and Health Admin-
istration (OSHA),
which mustweigh all
evidence before de-
ciding on any reduc-
tion in theworkplace
permissible exposure
Senator Raymond Willis, limit (PEL) for buta-
bber Czar" William M. diene. OSHAiscom-
nthetictire in 1942. mitted to reducing
worker exposure to the hydrocarbon. The
current 8-hour, time-weighted average work-
room PEL for butadiene is 1000 ppm, a fig-
ure set in 1981 aimed at preventing irritation
to the eyes andupper respiratorytract.
Today, because butadiene has been shown
to cause tumors in laboratory mice and rats
and because evidence suggests it is carcino-
genic in humans exposed occupationally, EPA
and the International Agency for Research on
Cancer rank butadiene as a probable human
carcinogen. In response to those same
research findings, OSHA has proposed lower-
ing the PEL to 2 ppm, but impelled by labo-
ratory findings oflow-dose exposure effects in
mice, the agency later this year may set an
even lower standard. The American
Conference of Governmental Industrial
Hygienists (ACGIH) last May listed butadi-
ene on its Notice of Intended Change. In
May 1994, an ACGIH subcommittee will
reviewthis notice, which calls forlowering the
workplace threshold limit value (TLV) from
10 ppm to 2 ppm. The ACGIH designation
of butadiene is A2: suspected carcinogen.
"Butadiene is definitely the bad actor in buta-
diene/styrene co-exposures," says Calvin
Wilhite oftheACGIH TLVcommittee.
"A range ofconcerns have been expressed
on butadiene's potential for human carcino-
genicity," says Ronald Melnick, NIEHS
senior toxicologist. "It includes the very con-
cerned to those who claim it doesn't exist for
humans."
The contention over this issue is revealed
in editorial commentary and scientific reports
since 1989 that demonstrate the authors' pas-
sions toward findings and implications.
Indeed, time and again, what some emphasize
to drive home a point, others view as misin-
terpretations of data. And when these same
scientists convene atsymposia to shedlight on
their latest work, it is not without some heat.
And yet summaries ofjoint conferences read
like exercises in restraint and editorial balance;
they betray no trace of the wrangling that
surely must have accompanied reaching agree-
ment on finalwording.
TheModel andtheMessage
Where do scientists agree on butadiene? None
deny its potency as a carcinogen in mice. The
carcinogenicity ofinhaled butadiene has been
studied in Sprague-Dawley rats by the
International Institute of Synthetic Rubber
Producers and in B63CF1 mice by researchers
in the U.S. National Toxicology Program
(NTP). A 1988 NIEHS international sympo-
sium on butadienepublished in EHP(volume
86) in 1990 included reports of butadiene-
induced neoplasms at multiple organ sites in
rats (pancreas, uterus, Zymbal gland, mam-
mary gland, thyroid, testis) and mice (lym-
phomas and neoplasms of the heart,
forestomach, lung, liver, mammary gland,
ovary, and preputial gland). In those studies,
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rats were exposed to butadiene by inhalation
at 1000 and 8000 ppm, and mice were
exposed at 625 and 1250 ppm.
Since then, an expanded NTP study on
male and female mice exposed to butadiene
inhalation at 0, 6.25, 20, 62.5, 200, and 625
ppm for up to 2 years has been completed.
Melnick and his colleagues observed butadi-
ene carcinogenicity in mice atall exposure lev-
els, including early, extensive induction of
malignant lymphomas, which again was the
major cause of early death for both sexes
exposed to 625 ppm. Incidence of lym-
phomas also increased for females at 200
ppm. Induction ofuncommon hemangiosar-
comas ofthe heart were observed at concen-
trations as low as 20 ppm. Malignant lung
tumors occurred at the 6.25 ppm level, the
lowest concentration ever used in a long-term
cancer study ofbutadiene. In Melnick's stop-
exposure studies of butadiene in mice, car-
cinogenesis in multiple organs was induced
after only 13 weeks ofexposure, and for lym-
phoma the concentration ofbutadiene was a
greater contributing factor than duration of
exposure.
Thus, butadiene exerts a clear carcino-
genic effect after relatively short periods of
exposure and at multiple organ sites in mice
exposed byinhalation in long-term studies. In
rats, the effect is less pronounced and requires
much larger doses to induce cancer and target
organs differ with the exception ofmammary
gland.
According to Melnick and NIEHS co-
author James Huff, the finding most relevant
to human risk is that mice show "good corre-
spondence" with reported associations
between occupational exposure to butadiene
and excess mortality from lymphatic and
hematopoietic cancers. This finding strength-
ens the argument that mice, rather than rats,
are a better experimental surrogate for
humans. Furthermore, Melnick and Huff
suggest that perhaps the rat is uniquely insen-
sitive to leukemia/lymphoma induction.
Similar to butadiene, the human leukemogen
benzene produces lymphomas in mice but not
in rats. Rats are also much less sensitive to
radiation-induced leukemia than mice.
Melnick and Huffconclude that,
based on the cumulative weight
ofevidence, there is a causal asso-
ciation between exposure to buta-
diene and human cancer, and
there is a vital public health need
to reduce exposure to this chemi-
cal.
Other reports, however, have
questioned the appropriateness of
extrapolating data on the carcino-
genicity of butadiene in mice to
carcinogenicity in humans. James Bon Arguments include laboratory rats and miu
observations ofspecies differences from predict
in butadiene metabolism. In vivo whatisactu
nd-
ice n
ctin
]ally
studies have illustrated species
differences among mice, rats,
and monkeys in low-level buta-
diene absorption, metabolism,
and retention. For example,
when looking at concentrations
of the metabolite butadiene
monoepoxide in the blood of
all three species after inhalation
of butadiene concentrations
ranging from 8 to 8000 ppm,
monkeys always had lower
blood epoxide concentrations RonaldMelaio than rats or mice. Metabolism causal relation
ofbutadiene byrodents, ingen- human cancer.
eral, may be qualitatively differ-
ent from primates. Recent studies ofbutadi-
ene metabolites in peoplehave also pointed to
these rodent-primate differences based on
metabolites in urine. This finding points to
something toxicologists have always known:
rodents are notperfectsurrogates forhumans.
Another focus, such as work underway at
the Chemical Industry Institute ofToxicology
(CIIT), has been on specific butadiene epox-
ides in liver and lung tissue samples of rats,
mice, and humans. Metabolic activation of
butadiene involves oxidation mediated byvar-
ious forms of cytochrome P450 (primarily
P450 261) to DNA-reactive (genotoxic)
metabolites such as butadiene monoepoxide.
Significant species differences in in vitro rates
of activation and deactivation of butadiene
epoxides presumably support the idea that
mice are far more sensitive to the carcinogenic
activity of butadiene than rats or humans.
Such interspecies comparisons of chemical
metabolism lead some to conclude that
human cancer risks from butadiene exposure
are similar to that of rats, which are more
resistant than mice to butadiene's carcino-
geniceffects. Findings obtained from this bio-
chemicallybased model ofbutadiene pharma-
cokinetics are meant to flash acaution light in
the eyes of regulators who rely on mouse
studies to assess risks.
James Bond, head ofbiochemical toxicol-
ogy at CIIT, cautions that metabolism does
not entirely explain species differences in
potency and organ-site specificity of butadi-
ene carcinogenicity. "But I do
2 think it's a critical factor," he
,says. "How those epoxides
° translate to a mutational event
mis unclear. Probably a combi-
nation ofdifferences in metab-
olism, potential mutagenicity,
and other species-related fac-
tors we don't understand may
someday tell us why mice, for
example, are more sensitive
than rats."
Indeed, differences in car- -Research In . r
eeds to move cinogenic sensitivity ot rats
g to studying and mice to inhaled butadiene
occurring. are so far only suggestive of a
cks
bul
toxicokinetic contribution. In a
z recent report, tissue concentra-
tions of butadiene monoepox-
ide, predicted in rats and mice
from a physiologically based
pharmacokinetic model of
uptake, tissue distribution, and
metabolism of butadiene, could
not account for differences in
tumor incidence in thesespecies.
Melnick has pointed out
i-There problems in data analysis ofthe
-There is a earlier biochemically based mod-
hidibenteaend elingstudywhich,when correct-
ed, indicates humans are not
necessarily as insensitive as had
been thought. "Other factors crucial for car-
cinogenesis induced by butadiene may
include accumulation of another epoxide,
diepoxybutane, formation of DNA adducts,
and efficiency of DNA repair." Still, none of
these factors has been predicted by current
physiologically based models.
Predictions by Melnick and colleague
Michael Kohn's physiologically based phar-
macokinetic model indicate release ofbutadi-
ene from storage in fatafter cessation ofexpo-
sure would result in continued epoxide pro-
duction in humans. This is not the case in
mice, Melnick and Kohn point out, adding
that results from acute exposure studies in
animals mayunderestimate the risk to human
health of repeated exposure to butadiene.
Bond notes, however, that other investigators,
including those at CIIT, also usingphysiolog-
ically based pharmacokinetic models, have
come to different conclusions regarding the
potential for storage of butadiene in tissues
like fat. The major reason for the differences
is the values for butadiene solubility in tissues
that areused in thevarious models.
"We need to go beyond tissue dosimetry
to understand the cancer process," Melnick
says. "Differences between rats and mice in
the doses ofepoxide occurring internally are
too small to explaindifferences in the carcino-
genic effects in these species." Yet Bond
points out that research needs to move away
from simply predicting what might be occur-
ringin rats andmice to actual studies ofepox-
ide levels in blood and target tissues ofthese
animals after butadiene exposures. "These are
key studies for validation of the dosimetry
models," hesays.
In addition to the debate on metabolic
differences are disagreements about retroviral
background. Studies on the potential of
endogenous murine leukemia virus (MLV) to
influence susceptibility to butadiene-induced
leukemia have also been cited as a reason for
caution against extrapolating findings in mice
to humans.
Studies by Richard D. Irons, director of
molecular toxicology and environmental
health sciences at the University ofColorado,
determined that B6C3F1 mice, which have
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MLV, have a remarkably high incidence of
butadiene-induced leukemia or thymic lym-
phoma. The incidence of lymphoma was
fourfold (57% versus 14%) that ofNIH Swiss
mice that do not have the virus in a 1-year
study of exposures at 1250 ppm butadiene.
Irons points out that these findings are bol-
stered by the fact that target organ toxicity in
the two strains is qualitatively and quantita-
tively identical after butadiene exposure dur-
ing the preleukemic phase of the study. Says
Irons, "Retroviral background influences the
ultimate incidence but doesn't account for
causation in toto."
According to other reports, however, buta-
diene is carcinogenic to Swiss mice, a strain
without MLV and with a near-zero back-
ground rate for thymic lymphoma, and to
Sprague-Dawley rats, in spite ofmetabolic and
pharmacokinetic differences. Melnick and
Irons agree that viruses alone cannot account
for the carcinogenic effects of butadiene
because the monomer induced a significant
incidence of lymphoma in NIH Swiss mice.
Moreover, Melnick adds, other genetic differ-
ences between the strains of mice could con-
tribute to the different tumor rates. And be-
cause the NTP studies were only 52 weeks
long, they do not necessarily reveal the full
response for lymphoma induction by
butadiene.
Mice exposed chronically to butadiene,
treated with radiation, or bearing "white-spot-
ted" or "steel" mutations show an identical
pattern ofdisease, which includes a high inci-
dence of leukemia and thymic lymphomas.
This pattern may indicate a functional defect
in a subpopulation ofprimitive hematopoietic
stem and progenitor cells, Irons explains.
These mutant mice lack the same subpopula-
tions of primitive hematopoietic stem and
progenitor cells that are susceptible to butadi-
ene suppression in intact mice. This, he says,
draws into serious question any reference to
the mouse as a quantitiative model in risk
assessment for humans. "Ifyou use the mouse
as a quantitative model, you do so at your
peril," Irons warns.
Butadiene Epidemiology
In terms of occupational butadiene exposure,
industrial hygiene data collected before 1980
are considered not particularly good because
most exposures were well below the OSHA
limit, few samples were used, and sampling
methodology was not rigorous. More recent
data compiled by NIOSH show the highest
butadiene exposures occur in the monomer
industry, where a mean airborne level of 5.9
ppm was found, with 7% ofsamples showing
levels greater than 10 ppm, and 20% greater
than 2 ppm, which is the level proposed by
OSHA. In the polymer industry (including
styrene-butadiene rubber, polybutadiene rub-
ber, and other polymers), mean airborne expo-
sure was 1.1 ppm, with 3% ofsamples show-
ing more than 10 ppm,
and 11% more than 2
ppm. However, maxi-
mum 8-hour time-
weighted average expo-
sures were frequently
between 10 and 150
ppm, and in one case
as high as 374 ppm, Low-Dose
forjobs involving buta- Carcinogen
diene transfer, sam-
pling, and mainte-
nance. In end-user
industries such as rub-
ber tire plants and How much butadiene
industrial hose plants, tumors in mice and higi
more than 100 samples is not known where hun
contained no detectable levels ofbutadiene.
Most epidemiological studies of exposure
to butadiene have used a retrospective cohort
design and included assessments based on
mortality data. These studies have consistently
indicated increased frequencies of lymphatic
and hematopoietic cancers. Quantitative
exposure data are lacking. A number ofobser-
vations, however, appear compelling in terms
oftheir applicability to assessing cancer risk in
humans due to butadiene exposure.
Cohort mortality studies have shown
lower overall mortality rates and lower mor-
tality from all cancers in workers occupation-
ally exposed to butadiene than rates for the
general population. This may be evidence ofa
"healthy worker effect," in which study results
may be skewed by the fact that someone who
is working is more likely to be healthy.
However, consistent among at least five epi-
demiological studies of workers exposed to
butadiene is the finding of excess mortality
from lymphatic and hematopoietic cancers.
Moreover, excess mortality from these cancers
among subgroups ofworkers, including black
production workers, was also observed.
Philip Landrigan, chairman ofcommuni-
ty and environmental medicine at Mt. Sinai
School of Medicine in New York, updated a
1990 critical assessment of these studies for
presentation to the 1993 International
Symposium on Health Hazards of Butadiene
and Styrene in Helsinki, Finland. All of the
epidemiologic studies, Landrigan points out,
share several shortcomings. Inadequate assess-
ment ofpast exposure is the greatest weakness
in all these studies, he says. The absence of
precise individual data tends to diminish the
likelihood of observing an etiologic associa-
tion. Another shortcoming is the inherent
inability of mortality studies to account for
the increasing longevity ofpatients with lym-
phatic and hematopoietic malignancy that has
been achieved with modern chemotherapy.
Mortality studies do not reflect incidence.
Failure to specifically examine black workers
in most of the studies overlooks an opportu-
nity to examine a subpopulation possibly at
high risk. There is also a failure to account
a? While low doses produce
h doses are required for rats; it
mans fall in the range.
adequately in co-
hort studies for
the healthy worker
effect, resulting in
underestimation
ofexcess mortality
attributable to bu-
tadiene exposure.
Finally, compari-
son to either the
general U.S. pop-
ulation or the gen-
eral population of
a particular region
may not be as ap-
propriate as com-
parison to a "blue
collar" population. Use ofsuch a group would
offer more precise comparison and lead to
more accurate estimation ofexcess mortality.
Evidence that the excess cancer mortality
is dose related is supported by observations
that mortalities are greatest in production and
maintenance workers, but not in office staff.
"Typically, production and maintenance
workers are the groups most heavily exposed
to potentially toxic substances," Landrigan
says. He cites as further evidence for a positive
dose-response link the observation ofgreatest
excess mortality among workers exposed dur-
ing the war years, presumably a period when
butadiene exposures were especially intense
due perhaps to wartime production pressures
and possible mishaps during start-up of the
industry.
A retrospective study of workers em-
ployed at two synthetic rubber plants in Texas
found excess mortality for lymphatic and
hematopoietic cancer in the older facility.
Standardized mortality ratios for lymphosar-
coma were two times the normal rate and for
leukemia almost three times normal, with
excesses for these malignancies most signifi-
cant among wartime workers.
What may account for the greater
leukemia rate among blacks, Landrigan says,
is the historical practice ofassigning the most
menial jobs to black workers. The tasks of
predominantly black "labor gangs" included
cleaning the inside of tanks that had held
butadiene. Racial segregation by job category
in at least one Texas facility apparently per-
sisted into the mid-1960s, according to
descriptions bylong-term workers.
Genevieve Matanoski ofJohns Hopkins
University has conducted the largest cohort
study and most recent case-control studies on
butadiene occupational exposure. She also
found excess mortality from lymphatic and
hematopoietic cancers despite an overall
deficit in cancer mortality, with the excess can-
cers (five times greater than background) most
prevalent in production and blackworkers.
Matanoski points out that cancer was also
observed among maintenance and production
workers in Canadian plants that had no black
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employees. She finds it
interesting that higher lymn-
phopoietic malignancy rates
among black production
workers (likely the most
heavily exposed in the sam- i
ple population) may estab-
lish a link with observations
in animal studies of in-
creased lymphoid and hem-
atopoietic cancers induced
by high concentrations of
butadiene. Philip Landrig
One criticism of the attempt should b
findings in blackproduction prevent exposure to
workers arose from an
analysis that showed lymphopoietic cancers
concentrated in short-term workers. John
Acquavella of Monsanto's epidemiology
department and chair of the International
Institute ofSynthetic Rubber Producer's epi-
demiology committee, says excess cancers in
short-term workers but not in long-term
workers is controversial because of the long
latency period required for mortality to occur
from these malignancies. "These workers had
lymphopoietic cancers when they were first
hired or shortly thereafter. We know very lit-
tle about work histories ofpeople before they
entered and after they left the industry, says
Acquavella."
"Here Acquavella is under a misconcep-
tion," Matanoski says. "Average employment
of these workers was more than 12 years.
That's certainly not short-term." She points
out that the cohort study at a butadiene man-
ufacturing facility in Texas showed high risk
in short-term workers. "But," she says, "that
meant 10 years or less, which is a long
employment, and most of the risk is in that
group." However, Matanoski agrees there's an
absence of data on hiring and employment
duration during industry start-up years.
"There were new plants, new people without
experience moving from one plant to another,
and lots of short-term workers became long-
termworkers."
Several other data classification factors
combine to make retrospective cohort analysis
difficult for epidemiolgists studying health
effects ofoccupational exposure to butadiene.
In spite ofattempts to classify jobs by butadi-
ene exposure, job titles are often nonspecific
and difficult to classify even in known expo-
sure categories. As Matanoski has reported,
one finds compressor operators working in
utilities, truckers in operation services, and
variation in exposure type by laboratory job.
Moreover, jobs within a work area may vary
widely in exposure rankings, so that exposed
jobs become diluted with nonexposed groups,
and thus exposure risk disappears. According
to Matanoski, case-control analysis (using
continuous variables in a logistic regression
model) offers a more specific way ofclassify-
ingeach individual byexposure rank.
lan-
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Questions have also been raised
a, about interpretation ofthe epidemi-
- ology results because ofan apparent
- lack of consistency in the types of
- lymphatic cancers observed to be
elevated in the different studies.
The argument is that such inconsis-
tencies represent etiologically dis-
tinct cancers. Landrigan points out,
however, that diagnostic categories
of lymphatic cancers are imprecise
and overlap. Transitions between
-Every different lymphatic cancers are fre-
nade to quently seen. In addition, these
itadiene. transitions are complicated by his-
torical changes in nomenclature;
certain lymphomas and certain leukemias
such as chronic lymphocytic leukemia are
considered to represent different clinical
expressions of the same process of malignan-
cy.
Says Landrigan, "Based on a very exten-
sive review of the epidemiologic and toxicity
literature, butadiene is a serious carcinogen. It
has been shown to be able to cause cancers in
animals and humans, and the types ofcancers
commonly result in leukemia and lymphosar-
coma. Every attempt should be made to pre-
vent occupational and environmental expo-
sure to butadiene."
Biomarkers and Butadiene
Exposure
Although occupational exposures to butadi-
ene have been reduced during recent years, it
may not be possible to deter-
mine through epidemiologic
methods whether current or
even proposed levels are ade-
quate to protect workers. This
makes biological monitoring
techniques very important. Of
two urinary metabolites-the
product ofepoxybutene hydrol-
ysis followed by glutathione
conjugation, and the product of
glutathione conjugation of
epoxybutene-only the former Genevieve
appears to be an effective bio- Racial segri
marker of human exposure to category led
butadiene. The product of diene exposu
epoxybutene hydrolysis has
been detected in humans exposed to butadi-
ene at concentrations as low as 3-4 ppm.
Researchers at the University of Texas
Medical Branch in Galveston report pilot
study findings that indicate the biological sig-
nificance of exposure to genotoxic chemicals
can be evaluated shortly after exposure by
measuring the levels of genetic damage in
exposedpopulations. Environmental toxicolo-
gist Jonathan Ward, Jr. and his colleagues
have investigated the frequency of mutations
Mu
ega
to
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at the HPRTlocus in lymphocytes from
workers exposed to butadiene. High expo-
sures were approximately 3.5 ppm and low
exposures were approximately 0.03 ppm.
Workers in theexposed areas hadsignificantly
higher frequencies of mutant lymphocytes
than both the less exposed and nonexposed
subjects. Urine specimens were also collected
and evaluated for the presence of butadiene-
specific metabolites. Urinary metabolite con-
centrations also correlated highly with expo-
sure. These results indicate that a biomarker
oflow-level butadiene exposure in humans is
associated with gene mutation. "It is nowwell
established that mutagenesis in cancer genes is
a major aspect ofcarcinogenesis," Ward says.
"Therefore, conceptually, ifyou see an eleva-
tion in a population exposed to a particular
substance, you should be concerned that the
increasewould lead to an increase in cancer."
Samples from follow-up studies are just
now beginning to be analyzed, Ward says. He
points out that current results indicate that an
occupational exposure limit proposal of2 ppm
may not be low enough to protect workers
from theadverse health effects ofbutadiene.
Louis Beliczky, former director of indus-
trial hygiene, safety and environmental affairs
for the United Rubber Workers, and now a
private consultant to industry and trade
unions he says that court litigation in Texas
and Louisiana on the health effects ofoccupa-
tional exposure to butadiene is beginning to
grow. Beliczky would like to see government
activity aimed at lowering workplace exposure
Y levels to below 0.5 ppm. "I see
_ no reason why industry can't
meet that. I know for a fact that
most monomer and polymer
g facilities can get down to 0.5
ppm, said Beliczky.
X | Following a review ofall the
reports and debate, leaders of
the Helsinki symposium con-
cluded that occupational expo-
sure to butadiene was "found to
be strongly associated with car-
atanoski- cinogenic risk." They point to a
tion by job number of areas still requiring
higher buta- further research to better evalu-
for blacks. ate effects at various exposure
levels. Among these areas are
studies on reproductive toxicity and a need
for further refinement ofphysiologically based
pharmacokinetic dose-response models to
clarify the relationship between exposure, the
dose that reaches the target, and biological
effects, and an understanding ofbasic biologi-
cal mechanisms responsible for the effects
observed. According to a number ofscientists
and health care clinicians, the pursuit ofthese
research objectives should not delay the
reduction ofhuman exposure to butadiene.
LeslieLang Leslie Lang has previously written for EHP about
pesticides.
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